We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
+24.08%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$831M
AUM Growth
+$122M
Cap. Flow
+$139M
Cap. Flow %
16.78%
Top 10 Hldgs %
79.3%
Holding
22
New
5
Increased
4
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$64.8M
2
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$29.8M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$25.7M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$24.3M
5
IMVT icon
Immunovant
IMVT
+$17M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$19.2M
2
KOD icon
Kodiak Sciences
KOD
+$13.7M
3
VRNA
Verona Pharma
VRNA
+$8.07M
4
IMGN
Immunogen Inc
IMGN
+$1.66M
5
DBVT
DBV Technologies
DBVT
+$445K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
1
Axsome Therapeutics
AXSM
$12.3B
$164M 19.69%
2,341,238
-3,742
-0.2% -$280K
NUVL
2
DELISTED
Nuvalent
NUVL
$113M 13.56%
2,451,819
-432,673
-15% -$19.2M
IMGN
3
DELISTED
Immunogen Inc
IMGN
$94.1M 11.32%
5,929,592
-100,000
-2% -$1.66M
APGE icon
4
Apogee Therapeutics
APGE
$10.2B
$62.6M 7.54%
+2,941,176
New +$64.8M
MRUS
5
DELISTED
Merus
MRUS
$44.4M 5.34%
1,881,345
+398,940
+27% +$9.67M
KNSA icon
6
Kiniksa Pharmaceuticals
KNSA
$4.97B
$43M 5.17%
2,474,561
+1,770,102
+251% +$29.8M
ARGX icon
7
argenx
ARGX
$56.1B
$41.2M 4.95%
83,747
+10,221
+14% +$5M
COGT icon
8
Cogent Biosciences
COGT
$6.9B
$34.7M 4.17%
3,558,975
– –
SLNO
9
DELISTED
Soleno Therapeutics
SLNO
$33.7M 4.06%
+1,142,473
New +$6.92M
ELVN icon
10
Enliven Therapeutics
ELVN
$3.8B
$29.1M 3.5%
2,131,369
+6,744
+0.3% +$114K
IMVT icon
11
Immunovant
IMVT
$8.28B
$28.8M 3.46%
+750,000
New +$17M
RYZB
12
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$27.1M 3.26%
+1,221,904
New +$25.7M
DNTH icon
13
Dianthus Therapeutics
DNTH
$5.78B
$26.4M 3.17%
+1,928,503
New +$24.3M
VRDN icon
14
Viridian Therapeutics
VRDN
$2.2B
$21M 2.53%
1,369,623
– –
TYRA icon
15
Tyra Biosciences
TYRA
$1.89B
$19.2M 2.31%
1,393,329
-23,669
-2% -$351K
ATXS
16
DELISTED
Astria Therapeutics
ATXS
$14.2M 1.71%
1,901,397
– –
TRVI icon
17
Trevi Therapeutics
TRVI
$2.57B
$11.3M 1.35%
5,163,287
-27,073
-0.5% -$61.2K
TERN
18
DELISTED
Terns Pharmaceuticals
TERN
$10.3M 1.23%
2,040,000
– –
DBVT
19
DBV Technologies
DBVT
$813M
$9.22M 1.11%
678,115
-28,381
-4% -$445K
SYRE icon
20
Spyre Therapeutics
SYRE
$8.7B
$4.64M 0.56%
378,421
-1
-0% -$13
KOD icon
21
Kodiak Sciences
KOD
$2.66B
– –
-1,985,245
Closed -$13.7M
VRNA
22
DELISTED
Verona Pharma
VRNA
– –
-381,939
Closed -$8.07M

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q3 2023 Portfolio in Review

As of Q3 2023, Fairmount Funds Management held 22 positions worth $831M, up 17% from $709M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Fairmount Funds Management deployed $139M of net new capital in Q3 2023, opening 5 new positions and adding to 4 existing holdings. Its largest new stake was Apogee Therapeutics: 2,941,176 shares worth $62.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Nuvalent, an estimated $19.2M trimmed.

  • Fairmount Funds Management's largest Q3 2023 buy was Apogee Therapeutics: 2,941,176 shares worth $62.6M.
  • Fairmount Funds Management added most to Kiniksa Pharmaceuticals in Q3 2023, an estimated $29.8M increase.
  • Fairmount Funds Management's biggest Q3 2023 reduction was Nuvalent, cutting an estimated $19.2M.
  • Fairmount Funds Management fully exited Kodiak Sciences in Q3 2023, selling an estimated $13.7M.
  • Fairmount Funds Management's ten largest holdings make up 79% of its $831M portfolio in Q3 2023.
  • Fairmount Funds Management opened 5 new positions and closed 2 in Q3 2023.
  • Fairmount Funds Management's portfolio value rose 17% quarter-over-quarter to $831M.

Based on Fairmount Funds Management's 13F filing for Q3 2023, filed 14 Nov 2023.